End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
1,517.4 BDT | +5.61% | +16.77% | +76.96% |
Nov. 12 | Libra Infusions Limited Announces Cash Dividend for the Year Ended June 30, 2021 | CI |
Nov. 07 | Libra Infusions Limited Announces Expansion of Large Brand New Dialysis Fluid Production Plant | CI |
Sales 2017 | 244M 2.23M | Sales 2018 * | - | Capitalization | 653M 5.95M |
---|---|---|---|---|---|
Net income 2017 | 6M 54.68K | Net income 2018 * | - | EV / Sales 2017 | 6,34x |
Net Debt 2017 | 894M 8.15M | Net cash position 2018 * | - 0 | EV / Sales 2018 * | - |
P/E ratio 2017 | 107x | P/E ratio 2018 * | Employees | 699 | |
Yield 2017 | 0,57% | Yield 2018 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
1 day | +5.61% | ||
1 week | +16.77% | ||
Current month | +4.71% | ||
1 month | +3.17% | ||
3 months | +84.02% | ||
6 months | +116.09% | ||
Current year | +76.96% |
1 week
1 146.00
1 526.60

1 month
1 095.30
1 560.00

Current year
652.50
1 720.00

1 year
652.50
1 720.00

3 years
512.20
1 720.00

5 years
438.90
1 720.00

10 years
230.42
1 720.00

Managers | Title | Age | Since |
---|---|---|---|
Roushon Alam
FOU | Founder | - | 1976 |
A.N.M. Mainuddin
DFI | Director of Finance/CFO | - | - |
Ayesha Alam
CHM | Chairman | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Roushon Alam
FOU | Founder | - | 1976 |
Ayesha Alam
CHM | Chairman | - | - |
Saira Alam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-03 | 1,517.4 | +5.61% | 26 871 |
23-12-03 | 1,436.8 | -0.85% | 39,438 |
23-11-30 | 1,449.1 | +5.37% | 55,638 |
23-11-29 | 1,375.3 | +6.25% | 36,416 |
23-11-28 | 1,294.4 | +6.25% | 39,490 |
End-of-day quote Dhaka Stock Exchange, December 03, 2023
More quotes
Libra Infusions Ltd is a Bangladesh-based company engaged in manufacturing of Intravenous (I.V.) fluid. The Company's products include LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400 AND LIBRET. Its products are medical necessities used in medical situations involving diarrheal disease, surgical operation, loss of blood, weakness and hospitalization in general. LIBOTT is used for rehydration at the time of water deficit, general weakness and post-surgical intervention. LIBOTT-10 is used for the treatment of jaundice, general weakness, eclampsia and pre-eclampsia. LIBOTT-25 is used in the emergency treatment of severe hypoglycemia. LIBOTT-S is used for rehydration during general weakness, water deficiency along with sodium, diuresis, intoxication and post-surgical intervention. LIBOTT-S JR fulfills water deficit along with low deficiency of sodium chloride and supplies energy for growing children.
Sector
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+76.96% | 20 M $ | |
+60.25% | 525 B $ | |
+47.59% | 454 B $ | |
-10.10% | 381 B $ | |
-5.55% | 262 B $ | |
-10.49% | 253 B $ | |
-15.22% | 221 B $ | |
+3.05% | 202 B $ | |
-8.49% | 200 B $ | |
-42.51% | 163 B $ |